Health Canada strengthens safety information for all opioid drugs
Health Canada held a Scientific Advisory Panel on Opioid Use and Contraindications, to consider whether the current contraindications for opioid use are sufficient, or whether labelling updates and other actions may be needed to reduce risks to Canadians.
After thoroughly assessing the Panel’s recommendations, Health Canada is working with manufacturers to update the Canadian labelling of all prescription opioid products.